Therapeutic antibodies under development for SARS‐CoV‐2

Ma, Zetong; Zhu, Mengmei; Zhang, Shuyi; Qian, Kunxi; Wang, Chuqi; Fu, Wenyan; Lei, Changhai

doi:10.1002/viw.20200178

Cited by 4 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For SARS‐CoV‐2 virus infection, the first step is binding of the viral trimeric spike protein to the membrane‐bound form of the cellular receptor angiotensin‐converting enzyme 2 (ACE2) 13 . The ACE2 recombinant protein shows a great potential for inhibiting SARS‐CoV‐2 infection 14 . Our previous study developed an inhaled ACE2‐engineered microfluidic microsphere for neutralization of COVID‐19 15 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nanoantidote for repression of acidosis pH promoting COVID‐19 infection

Liu

Ruan

Sheng

et al. 2022

VIEW

View full text Add to dashboard Cite

Acidosis, such as respiratory acidosis and metabolic acidosis, can be induced by coronavirus disease 2019 (COVID‐19) infection and is associated with increased mortality in critically ill COVID‐19 patients. It remains unclear whether acidosis further promotes SARS‐CoV‐2 infection in patients, making virus removal difficult. For antacid therapy, sodium bicarbonate poses great risks caused by sodium overload, bicarbonate side effects, and hypocalcemia. Therefore, new antacid antidote is urgently needed. Our study showed that an acidosis‐related pH of 6.8 increases SARS‐CoV‐2 receptor angiotensin‐converting enzyme 2 (ACE2) expression on the cell membrane by regulating intracellular microfilament polymerization, promoting SARS‐CoV‐2 pseudovirus infection. Based on this, we synthesized polyglutamic acid‐PEG materials, used complexation of calcium ions and carboxyl groups to form the core, and adopted biomineralization methods to form a calcium carbonate nanoparticles (CaCO3‐NPs) nanoantidote to neutralize excess hydrogen ions (H+), and restored the pH from 6.8 to approximately 7.4 (normal blood pH). CaCO3‐NPs effectively prevented the heightened SARS‐CoV‐2 infection efficiency due to pH 6.8. Our study reveals that acidosis‐related pH promotes SARS‐CoV‐2 infection, which suggests the existence of a positive feedback loop in which SARS‐CoV‐2 infection‐induced acidosis enhances SARS‐CoV‐2 infection. Therefore, antacid therapy for acidosis COVID‐19 patients is necessary. CaCO3‐NPs may become an effective antacid nanoantidote superior to sodium bicarbonate.

show abstract

Section: Introductionmentioning

confidence: 99%

“… 13 The ACE2 recombinant protein shows a great potential for inhibiting SARS‐CoV‐2 infection. 14 Our previous study developed an inhaled ACE2‐engineered microfluidic microsphere for neutralization of COVID‐19. 15 ACE2 is expressed not only in lung, but also in blood vessels, as well as in other tissues.…”

Section: Introductionmentioning

confidence: 99%

Nanoantidote for repression of acidosis pH promoting COVID‐19 infection

Liu

Ruan

Sheng

et al. 2022

VIEW

View full text Add to dashboard Cite

show abstract

Therapeutic antibodies under development for SARS‐CoV‐2

Zhu

Zhang

et al. 2021

VIEW

Self Cite

View full text Add to dashboard Cite

The world is experiencing one of the most difficult moments in history with COVID‐19, which has rapidly developed into a worldwide pandemic with a significant health and economic burden. Efforts to fight the virus, including prevention and treatment, have never stopped. However, no specific drugs or treatments have yet been found. Antibody drugs have never been absent in epidemics such as SARS, MERS, HIV, Ebola, and so on in the past two decades. At present, while research on the SARS‐CoV‐2 vaccine is in full swing, antibody drugs are also receiving widespread attention. Several antibody drugs have successfully entered clinical trials and achieved impressive therapeutic effects. Here, we summarize the therapeutic antibodies against SARS‐CoV‐2, as well as the research using ACE2 recombinant protein or ACE2‐Ig fusion protein.

show abstract

Plasmonic Approaches for the Detection of SARS-CoV-2 Viral Particles

et al. 2022

View full text Add to dashboard Cite

The ongoing highly contagious Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), underlines the fundamental position of diagnostic testing in outbreak control by allowing a distinction of the infected from the non-infected people. Diagnosis of COVID-19 remains largely based on reverse transcription PCR (RT-PCR), identifying the genetic material of the virus. Molecular testing approaches have been largely proposed in addition to infectivity testing of patients via sensing the presence of viral particles of SARS-CoV-2 specific structural proteins, such as the spike glycoproteins (S1, S2) and the nucleocapsid (N) protein. While the S1 protein remains the main target for neutralizing antibody treatment upon infection and the focus of vaccine and therapeutic design, it has also become a major target for the development of point-of care testing (POCT) devices. This review will focus on the possibility of surface plasmon resonance (SPR)-based sensing platforms to convert the receptor-binding event of SARS-CoV-2 viral particles into measurable signals. The state-of-the-art SPR-based SARS-CoV-2 sensing devices will be provided, and highlights about the applicability of plasmonic sensors as POCT for virus particle as well as viral protein sensing will be discussed.

show abstract

Therapeutic antibodies under development for SARS‐CoV‐2

Cited by 4 publications

References 50 publications

Nanoantidote for repression of acidosis pH promoting COVID‐19 infection

Nanoantidote for repression of acidosis pH promoting COVID‐19 infection

Therapeutic antibodies under development for SARS‐CoV‐2

Plasmonic Approaches for the Detection of SARS-CoV-2 Viral Particles

Contact Info

Product

Resources

About